Redenlab supporting Larimar Therapeutics in Phase 1 SAD Clinical Trial

Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.

Click here to learn more.

Tags: ,

Related Post

Redenlab study featured in the Huberman Lab Podcast

  • Posted on 27 April, 2023
    Redenlab have been featured in the Huberman Lab Podcast for their study on “Adults with a history of recreational cannabis...
    Read more

    The L16HTHOUSE Study

    • Posted on 30 March, 2023
      L16HTHOUSE is a research trial testing an experimental medication for treating speech, motor, learning, and other developmental delays in children...
      Read more

      Dietary fat supplement trial for A-T

      • Posted on 30 March, 2023
        Ataxia telangiectasia (A-T) is a rare inherited condition that affects the nervous and immune systems. A-T typically impacts movement, vision...
        Read more